Hikma Pharmaceuticals (LON: HIK) revenue
Hikma Pharmaceuticals reported revenue of $3,349m for fiscal 2025, 7.1% more than in fiscal 2024 ($3,127m). Since fiscal 2020 its revenue has grown by 43.1%, an average growth of 7.4% a year.
Hikma Pharmaceuticals has grown its revenue for 3 years in a row, and fiscal 2025 is the highest of its 6 fiscal years on record. The biggest drop was in fiscal 2022, −1.4%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $3,349m | +7.1% | $542.0m | 16.2% |
| 2024 | $3,127m | +8.8% | $612.0m | 19.6% |
| 2023 | $2,875m | +14.2% | $367.0m | 12.8% |
| 2022 | $2,517m | −1.4% | $282.0m | 11.2% |
| 2021 | $2,553m | +9.1% | $582.0m | 22.8% |
| 2020 | $2,341m | — | $579.0m | 24.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Hikma Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Hikma Pharmaceuticals ranks 16th of the 59 Spanish and European health care companies with a page on Celsmar. The sector median grew 4.5% in its latest fiscal year; Hikma Pharmaceuticals, 7.1%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 14th | Getinge | SEK 34,969m | 0.6% |
| 15th | Demant | DKK 22,971m | 2.5% |
| 16th | Hikma Pharmaceuticals | $3,349m | 7.1% |
| 17th | Sartorius Stedim Biotech | €2,968m | 6.7% |
| 18th | Amplifon | €2,396m | −0.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in health care stocks.
Questions about the revenue of Hikma Pharmaceuticals
- How much revenue did Hikma Pharmaceuticals make in fiscal 2025?
- Hikma Pharmaceuticals reported revenue of $3,349m for fiscal 2025, compared with $3,127m in fiscal 2024.
- How much has the revenue of Hikma Pharmaceuticals grown?
- Between fiscal 2020 and fiscal 2025 it went from $2,341m to $3,349m: 43.1% more, an average growth of 7.4% a year.
- What was the best year for revenue at Hikma Pharmaceuticals?
- Of its last 6 fiscal years, fiscal 2025, with $3,349m.
- Where does Hikma Pharmaceuticals rank in its sector by revenue?
- It ranks 16th of the 59 Spanish and European health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Hikma Pharmaceuticals come from?
- From the report Hikma Pharmaceuticals files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Hikma Pharmaceuticals files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Hikma Pharmaceuticals: the Hikma Pharmaceuticals page · annual accounts · net income.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.